US · Healthcare · Biotechnology
EPS came in at 0.18 against a street estimate of 0.14 — a beat of 28.6%.
Analysts rate Zevra Therapeutics Inc. a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $25.25.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.60% |
| FMR Inc | 8.28% |
| Woodline Partners LP | 8.06% |
| Nantahala Capital Management, LLC | 6.05% |
| Vanguard Capital Management, LLC | 4.44% |
| State Street Corp | 2.83% |
| Geode Capital Management, LLC | 2.59% |
| D. E. Shaw & Co LP | 2.20% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Revenue was $37.756 million in Q3 2026, up from $26.063 million in Q3 2025; nine-month revenue was $113.639 million versus $72.345 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net revenue was $37.8 million, up 45% from $26.1 million in Q3 2025. • MIPLYFFA generated $34.0 million of Q3 2026 net r | 2026-11-03 |
| Quarterly report · Q2 2026 ZEVRA THERAPEUTICS, INC. — Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & investments (combined): $260.2 million as of June 30, 2026 ($145.3M c | 2026-08-05 |
| Results announced · Q3 2026 ZEVRA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 net revenue: $39.7 million (up 53% vs. Q2 2025's $25.9 million) • MIPLYFFA r | 2026-08-05 |
| Shareholder vote results · Q2 2026 ZEVRA THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Shareholder Voting Participation: 46,326,616 shares voted out of 59,114,850 outstandi | 2026-06-05 |
| Quarterly report · Q1 2026 ZEVRA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q1 2026): $36.2 million vs. $20.4 million (Q1 2025) – 78% increase • Net | 2026-05-06 |
| Results announced · Q2 2026 ZEVRA THERAPEUTICS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 net revenue: $36.2 million (78% increase vs. Q1 2025's $20.4 million) • Net | 2026-05-06 |
| Proxy statement · Q2 2026 ZEVRA THERAPEUTICS, INC. – 2026 PROXY SUMMARY CEO COMPENSATION & CHANGE • Neil F. McFarlane (President and CEO) total compensation: Not explicitly s | 2026-04-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zevra Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.